Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1

Oncology Letters

Volumn 3, Issue 1, 2012, Pages 135-140

  Bai, Zhigang ^a   Zhang, Zhongtao ^a   Qu, Xiang ^a   Han, Wei ^a   Ma, Xuemei ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Multidrug resistance; Taxol resistance; Taxol resistance gene 1; Thrombospondin 1

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; GLUTATHIONE TRANSFERASE P1; PACLITAXEL; PROTEIN; SMALL INTERFERING RNA; TAXOL RESISTANCE PROTEIN 1; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CHEMOSENSITIVITY; DRUG SENSITIZATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84855244929     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.416     Document Type: Article

References (22)

1. Marsh S and McLeod HL: Pharmacogenetics and oncology treatment for breast cancer. Expert Opin Pharmacother 8: 119-127, 2007.
2. Moore A: Breast-cancer therapy-looking back to the future. N Engl J Med 357: 1547-1549, 2007.
3. Horwitz SB: Mechanism of action of taxol. Trends Pharmacol Sci 13: 134-136, 1992.
4. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC and Davidson NE: Weekly paclitaxel in the adjuvant treatment of breast cancer. New Engl J Med 358: 1663-1671, 2008.
5. Broxterman HJ, Gotink KJ and Verheul HM: Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat 12: 114-126, 2009.
6. Sangrajrang S and Fellous A: Taxol resistance. Chemotherapy 46: 327-334, 2000.
7. Martello LA, Verdier-Pinard P, Shen HJ, He L, Torres K, Orr GA and Horwitz SB: Elevated levels of microtubule destabilizing factors in a taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res 63: 1207-1213, 2003.
8. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002.
9. Ferguson T, Wilcken N, Vagg R, Ghersi D and Nowak AK: Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 17: CD004421, 2007.
10. Kutuk O and Letai A: Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res 68: 7985-7994, 2008.
11. Hudis C and Dang C: The taxane limbo: how low can we go? J Natl Cancer Inst 100: 761-763, 2008.
12. Lih CJ, Wei W and Cohen SN: Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev 20: 2082-2095, 2006.
13. Nor JE, Mitra RS, Sutorik MM, Mooney DJ, Castle VP and Polverini PJ: Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 37: 209-218, 2000.
14. Papadaki C, Mavroudis D, Trypaki M, Koutsopoulos A, Stathopoulos E, Hatzidaki D, Tsakalaki E, Georgoulias V and Souglakos J: Tumoral Expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen. Clin Cancer Res 15: 3827-3833, 2009.
15. Greenberger LM, Lothstein L, Williams SS and Horwitz SB: Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines. Proc Natl Acad Sci USA 85: 3762-3766, 1988.
16. Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253-265, 2004.
17. Van Amerongen R and Berns A: TXR1-mediated thrombo-spondin repression: a novel mechanism of resistance to taxanes? Genes Dev 20: 1975-1981, 2006.
18. Orr GA, Verdier-Pinard P, McDaid H and Horwitz SB: Mechanisms of taxol resistance related to microtubules. Oncogene 22: 7280-7295, 2003.
19. Ark-Otte J, Samelis G, Rubio G, Lopez Saez JB, Pinedo HM and Giaccone G: Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 5: 249-255, 1998.
20. McGrogan BT, Gilmartin B, Carney DN and McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 1785: 96-132, 2008.
21. Lavie Y, Cao H, Volner A, Lucci A, Han TY, Geffen V, Giuliano AE and Cabot MC: Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 272: 1682-1687, 1997.
22. Longley D and Johnston P: Molecular mechanisms of drug resistance. J Pathol 205: 275-292, 2005.